Under the title "German Experimental Heart Drug Miraculously Eliminates Coronavirus," Al Arabiya published a report about a remarkable coincidence that led German doctors to optimism in using a new experimental heart medication to treat "COVID-19" and its aftermath. They administered a dose of it to a 59-year-old heart patient, and after a few hours, they discovered that BC 007, intended for treating heart failure due to coronary artery disease, completely eradicated the remnants of a "coronary" infection the patient had previously suffered. Although it treated and cured the infection, the patient continued to experience its symptoms.
Symptoms of this condition, referred to by doctors as Long Covid, affect one in eight individuals overall and can last for months even after recovery, including shortness of breath and memory issues resembling dementia, according to Al Arabiya's report from today's British newspaper "The Times." The report discusses the experimental treatment and German doctors' verification of its potential use for treating the various forms of the novel coronavirus.
The drug, developed by Berlin Cures, a biotechnology holding company, completely eliminated the symptoms of "long-term COVID" and may even eliminate the root cause of the infection, as optimistic doctors at Erlangen University Hospital in Bavaria observed. The heart patient had been experiencing fatigue, loss of taste, and difficulty concentrating before being saved by a dose of experimental BC 007, as its effects were immediate. He regained his sense of taste and concentration, and physical symptoms vanished, allowing him to leave the hospital after three days.
Among those optimistic about the experimental drug's quick response to the virus is a 35-year-old ophthalmologist at the hospital, Bettina Hohberger. She explained that the body's immune defenses are "important in themselves, but they can sometimes turn against it and create harmful substances," explaining why symptoms of "long-term COVID" might persist even after the primary infection has been treated. She added to the British newspaper that she had intended to test the drug on glaucoma patients who had an abundance of antibodies but found that the experimental BC 007 works against some types of "long-term COVID" as well.
